All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Apremilast for oligoarticular PsA: Results from the phase IV FOREMOST trial
By Ella Dixon
|
Oligoarticular is a common PsA phenotype, affecting up to 50% of patients, but it is not well studied. FOREMOST (NCT03747939), a phase IV multicenter, randomized controlled trial assessed the safety and efficacy of apremilast, a phosphodiesterase-4 inhibitor, in early oligoarticular PsA (≤4 tender/swollen joints). Results were published by Gossec et al. in Annals of Rheumatic Disease. |
| Key learnings |
| At 16 weeks, more patients on apremilast achieved the primary endpoint of MDA-Joints response compared with placebo (33.9% vs 16.0%, p = 0.0008). |
| Apremilast showed better results for clinical disease activity, patient-reported outcomes (including pain reduction and functional improvement), and skin manifestations at Week 16. |
| The safety profile of apremilast was consistent with known data; the most common adverse events in the apremilast and placebo groups were headaches (7.8% vs 2.9%), nausea (10.8% vs 3.8%), and diarrhea (23% vs 10.6%). |
| The FOREMOST trial suggests apremilast is effective in treating early oligoarticular PsA and may inform appropriate management in these patients. However, additional studies are needed to confirm these findings. |
Abbreviations: MDA, minimal disease activity; PsA, psoriatic arthritis.
- Gossec L, Coates L, Gladman D, et al. Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial. Ann Rheum Dis. 2024;83(11):1480-1488. DOI: 1136/ard-2024-225833
More about...
Your opinion matters
10 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox